Byron Ellis, MD
Cardiovascular Disease · Sugar Land, TXNPI 1821046780
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $88,810 of the $117,737 with a category attached, or 75.4%. Johnson & Johnson accounts for 69.7% of it on its own, with 51 other manufacturers making up the rest. Reporting peaked in 2019 at $32,150 and has fallen 85.4% since, to $4,709 in 2025. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 791 payments — averaging $148.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$82K
- Shockwave Medical, Inc$13K
- Abbott$8K
- Medtronic$3K
- Boston Scientific$2K
- Novartis$1K
- plus $9K from 46 others
Across 22 payments — averaging $1181.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$21K
- Boehringer Ingelheim International GmbH$5K
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$88,81075%
- Travel & lodging$11,31610%
- Food & beverage$17,28015%
- Education$310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$80,210
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$12,595
- XIENCE SKYPOINT$2,415
- Xience V coronary stent system$1,712
- Resolute$1,567
- WATCHMAN Access System$1,382
- SUPERA$974
- OPTIMIZER$555
- Impella$548
- Omnilink Elite vascular stent system$532
- ACCULINK$461
- OPTIS$443
- Barostim Neo System$207
- Indigo System$171
- Xience Sierra Coronary Stent$166
- Supera peripheral stent system$130
- CoreValve Evolut$128
- COREVALVE EVOLUT R$116
How this compares
$117,737 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 497 | $524,113 |
| EliquisApixaban | 278 | $317,970 |
| EntrestoSacubitril/Valsartan | 207 | $240,546 |
| Repatha SureclickEvolocumab | 170 | $139,833 |
| Praluent PenAlirocumab | 95 | $70,797 |
| BrilintaTicagrelor | 76 | $55,561 |
| FarxigaDapagliflozin Propanediol | 36 | $41,431 |
| Metoprolol Succinate | 1,060 | $16,584 |
| Valsartan | 345 | $14,913 |
| Losartan Potassium | 1,053 | $13,852 |
| Flecainide Acetate | 271 | $12,889 |
| Nebivolol Hcl | 201 | $12,597 |
| VascepaIcosapent Ethyl | 23 | $12,217 |
| Rosuvastatin Calcium | 835 | $12,150 |
| Prasugrel Hcl | 157 | $11,496 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $82,032 | $524,113497 claims |
| PfizerEliquis | $623 | $317,970278 claims |
| NovartisEntresto | $1,322 | $240,546207 claims |
| AstraZenecaBrilinta, Farxiga | $803 | $96,992112 claims |
| Boehringer IngelheimJardiance | $398 | $7,25211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Sugar Land
- George MillerSugar Land$168K
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Robert SalazarKingwood$478K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.